📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
7 articles scientifiques publiés — formation continue solide
Référence presse grand public
Cité 5 fois dans les médias — pédagogie reconnue
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
8
8 articles ont été cités au moins 8fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
h-index
Total citations reçues
2 351
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
16
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
7
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Assistance Publique – Hôpitaux de Paris
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Validation study of “Santé-Cerveau”, a digital tool for early cognitive changes identification
2023ArticleAlzheimer's Research and Therapy
Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers
2020ArticleNeurobiology of Aging
Pour une prise en charge préventive de la maladie d’Alzheimer
2020ArticleBulletin de l'Académie Nationale de Médecine
Biomarker-guided clustering of Alzheimer's disease clinical syndromes
2019ArticleNeurobiology of Aging
Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease
2019ArticleAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Effect of Alzheimer's disease risk and protective factors on cognitive trajectories in subjective memory complainers: An INSIGHT‐preAD study
2018ArticleAlzheimer's & Dementia : the Journal of the Alzheimer's Association
Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology
2018ArticleJournal of Alzheimer's Disease
Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study
2018ArticleThe Lancet Neurology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Le Quotidien du Médecin · 07/05/2025
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxOaGZVVGJuZDVwSkE2eGtyUENqSDF0V01fcVo1UU1EdmxrM2paSlpDVjlzYW9XY0o4eU5pVFlVN09GWFhocWYyUUJKamZpX09HLUFwUDlOcFZjWXY2LXREWUtuMjl0NjNuTHdtbEpQQjdTT3Y2UHFmNHUxd0JFT3RzR0JuQ2dxZXJjLTIyV1h3VUdQSm04RnJzS2dER0JxLS1GWEsyZWFJeVpWQW5BQ0JHLVRpNUhQY3RNNz
📰 Journal des Femmes Santé · 06/11/2025
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxNYzlNbXRpTzVodmFvMDBRaEg3a3lQSGVNd3dveFhxZGJNd2ZHT01HOFd6M3F3OERVZE0wdmI3ZnVJZmU4NVp0b1B3dXM5REY4eFRhU0tSWm54OWFNRGk1dnpuMjdqSDVQOTRPWTBDVjRCaHVKZi1MbC1VVmM4Und0a0NfODRkak9oZzRIRE4tbjdTWmlfNTZ5cFg5cFlYY3d0Q296aUEzcXV4amxMLU04dTdpN3lUT01qUk
📰 Pharmaceutiques · 20/11/2025
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPR3d5RTk1X0RpRkg0YlNkTGpMbnBfa1Rmb0Q1bHpaUmN2LWVnVmNyaEY2Mk1LSTBlS3oxMHMwaGF4R0w3RDh1RjlWaGQzc3VjVUFBcFVlSVNKLXExNHIyMktlR25xLTh1MDBvekFTOFlPMkUzQ1pUTlhLamY1aTZFRmdQUFhMbzQ3LVBRS2NHeVhJdU15ZTN4QUQxN2UwOHcyTHhxN2RRWVI0QQ?oc=5" target="_blan
📰 Femme Actuelle · 20/09/2025
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQdF9WODdrdUxLNS1wM3ZDNjBvRmpiXzhGc1BHNS1Md3JDR1lhN0pTTGJZVkFnR05GT2VXTXVkRk1FU0ZzQ1EtM1F2Z285eFBwOFBfaXVPal9kcGRRYU1weklBXzlVMVNjWWNVTEVSSFFINlJlQS1wV0s0SzZLdkZzN0trQzZrTG43cFp1eURMRzVDdXFhZ29oNHY3NTBNUzltRzc3dlR2SlJrNC16Uk5OOTFDa2VwYlYtVT
📰 Journal des Femmes Santé · 21/01/2022
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPV0NqUy1BdFdkY0pFYWp2bEV5bGhGVFN5NjI4dF9WRXBETWdsOFpGdFlHclZSREhIWW5KajVodlB3VTZjN2tMV3l4T01QSXNfQUpmb1k2cGw2bkRZYWlVYUtoRFVkVDdIcWlJam5BbEx4RG40UnkyNWhKSlZLMnNRLU91VkF2STVpbk9LT1ZFWWxOaHpaRWYwNnQ5TTZFaGY0WUE?oc=5" target="_blank">Protéine
Alzheimer's & dementia : the journal of the Alzheimer's Association · 2016
AbstractDuring the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this “silent” stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.
The Lancet. Neurology · 2018
Journal of Alzheimer's disease : JAD · 2018
The Precision Neurology development process implements systems theory with system biology and neurophysiology in a parallel, bidirectional research path: a combined hypothesis-driven investigation of systems dysfunction within distinct molecular, cellular, and large-scale neural network systems in both animal models as well as through tests for the usefulness of these candidate dynamic systems biomarkers in different diseases and subgroups at different stages of pathophysiological progression. This translational research path is paralleled by an “omics”-based, hypothesis-free, exploratory research pathway, which will collect multimodal data from progressing asymptomatic, preclinical, and clinical neurodegenerative disease (ND) populations, within the wide continuous biological and clinical spectrum of ND, applying high-throughput and high-content technologies combined with powerful computational and statistical modeling tools, aimed at identifying novel dysfunctional systems and predictive marker signatures associated with ND. The goals are to identify common biological denominators or differentiating classifiers across the continuum of ND during detectable stages of pathophysiological progression, characterize systems-based intermediate endophenotypes, validate multi-modal novel diagnostic systems biomarkers, and advance clinical intervention trial designs by utilizing systems-based intermediate endophenotypes and candidate surrogate markers. Achieving these goals is key to the ultimate development of early and effective individualized treatment of ND, such as Alzheimer’s disease. The Alzheimer Precision Medicine Initiative (APMI) and cohort program (APMI-CP), as well as the Paris based core of the Sorbonne University Clinical Research Group “Alzheimer Precision Medicine” (GRC-APM) were recently launched to facilitate the passageway from conventional clinical diagnostic and drug development toward breakthrough innovation based on the investigation of the comprehensive biological nature of aging individuals. The APMI movement is gaining momentum to systematically apply both systems neurophysiology and systems biology in exploratory translational neuroscience research on ND.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The Lancet. Neurology · 2018 · Journal Article
Dubois B, Epelbaum S, Nyasse F, Bakardjian H, et al.
Pharmacological research · 2018 · Journal Article
Hampel H, Vergallo A, Aguilar LF, Benda N, et al.
Journal of Alzheimer's disease : JAD · 2018 · Journal Article
Hampel H, Toschi N, Babiloni C, Baldacci F, et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association · 2016 · Journal Article
Dubois B, Hampel H, Feldman HH, Scheltens P, et al.
Neurobiology of aging · 2019 · Journal Article
Toschi N, Lista S, Baldacci F, Cavedo E, et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018 · Journal Article
Hampel H, Toschi N, Baldacci F, Zetterberg H, et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association · 2017 · Journal Article
Epelbaum S, Genthon R, Cavedo E, Habert MO, et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association · 2017 · Journal Article
Epelbaum S, Genthon R, Cavedo E, Habert MO, et al.